Neurocrine initiated with Outperform at Bernstein on long runway of key drugs

Bernstein analyst Jeffrey Walch initiated coverage of Neurocrine (NBIX) with an Outperform rating and $221 price target The firm sees the compa...

Raccontata damarkets.businessinsider.com